Regeneron reports Pasatru data and Regeneron stock trades at EUR 677.30

Published on 10/14/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pasatru produced zero new lesions versus nine for placebo at week 84. Regeneron stock trades at EUR 677.30 on October 14, 2026.

Pasatru evidence and upcoming report

Pasatru produced zero new lesions versus nine for placebo at week 84 on October 12, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock trades at EUR 677.30 at 1:47 p.m. CEST at Lang & Schwarz on October 14, 2026.
Regeneron will report third-quarter results on October 30, 2026.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) was trading at EUR 677.30 at Lang & Schwarz on October 14, 2026 at 1:47 p.m. CEST. On October 12, 2026, BioSpace reported that Pasatru produced zero new heterotopic ossification lesions from week 56 to week 84, versus nine for placebo.

Three dated developments

On July 30, 2026, Regeneron filed its second-quarter report, with revenue of USD 4.29 billion, up 16.70 percent from the same quarter a year earlier. GreekSoup also lists net income of USD 1.30 billion and diluted earnings per share of USD 12.23 for the quarter ended June 30, 2026.

On September 24, 2026, Regeneron announced that it would report third-quarter 2026 results on October 30, 2026, before the U.S. financial markets open. The company scheduled its conference call for 8:30 a.m. Eastern Time, according to Regeneron.

On October 12, 2026, the company presented the 84-week OPTIMA extension results for Pasatru. The trial enrolled 63 adults, while 58 participants continued into the extension phase, and the treatment groups recorded one and 14 clinician-assessed flare-ups compared with 17 for placebo, according to BioSpace.

What does Pasatru change?

The clinical result gives Regeneron a concrete rare-disease commercial asset, but the safety detail remains relevant: skin and soft-tissue infections occurred in 33.00 percent of placebo patients, 53.00 percent of patients receiving Pasatru 3 mg/kg and 78.00 percent receiving 10 mg/kg. BioSpace reported that all infections resolved and no patient discontinued treatment because of infection.

Next reporting date

The next scheduled company milestone is October 30, 2026, when third-quarter results and operating commentary are due before the U.S. market open. That report will provide the next quantified test of the USD 4.29 billion quarterly revenue base and the USD 12.23 diluted earnings per share reported for the second quarter.

Market value and yearly range

Regeneron had a market capitalization of USD 77.6 billion and a 52-week Nasdaq range of USD 564.00 to USD 859.34 in the October 13, 2026 market snapshot. The Lang & Schwarz quote is therefore the German investor reference, while the Nasdaq figures provide separate home-market context.

Trading reference remains current

Regeneron stock was trading at EUR 677.30 at Lang & Schwarz on October 14, 2026 at 1:47 p.m. CEST. No percentage comparison is stated because the dated Xetra closing reference required for the calculation is not included here. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.